At 8.7% CAGR, the South & Central America Glioma Treatment Market is projected to be worth US$ 227.74 million by 2030, says Business Market Insights

According to Business Market Insights’ research, the South & Central America glioma treatment market was valued at US$ 117.14 million in 2022 and is expected to reach US$ 227.74 million by 2030, registering a CAGR of 8.7% from 2022 to 2030. Increase in prevalence of high-grade glioma and increasing drug approval for glioma treatment are among the critical factors attributed to the South & Central America glioma treatment market expansion.

In recent years, there has been a notable increase in the approval of drugs to treat gliomas, marking a significant step forward in addressing the challenges posed by these severe brain tumors. Growing awareness of the urgent need for effective therapeutic options and the dedicated efforts of researchers and pharmaceutical companies to develop innovative treatments are leading to the development and approval of these drugs. Targeted therapies have been a key focus of researchers working on glioma treatment, wherein drugs are designed to specifically target molecular alterations or signaling pathways crucial for glioma cells' survival and growth. These therapies aim to disrupt the tumor's ability to expand while sparing healthy brain tissue. In June 2022, the FDA approved two targeted therapy drugs to be taken in combination—Dabrafenib and Trametinib. These drugs attack the cancerous cells that have undergone the BRAF mutation. The drugs stop the mutated cells from sending growth signals to other cells.

Drug manufacturers have been emphasizing the use of cutting-edge technologies. Kiyatec's ex vivo 3D cell culture technology for high-grade glioma received new clinical data at ASCO 2022. Thus, an increasing number of drug approvals for treating glioma would result in notable growth trends in the glioma treatment market in the near future.

On the contrary, the high cost of diagnosis hampers the South & Central America glioma treatment market.

Based on disease, the South & Central America glioma treatment market is segmented into astrocytoma, oligoastrocytoma, and oligodendroglioma. The astrocytoma segment held 70.7% share of South & Central America glioma treatment market in 2022, amassing US$ 82.82 million. It is projected to garner US$ 165.92 million by 2030 to expand at 9.1% CAGR during 2022–2030.

Based on treatment type, the South & Central America glioma treatment market is segmented into surgery, chemotherapy, radiation therapy, and others. The surgery segment held 47.9% share of South & Central America glioma treatment market in 2022, amassing US$ 56.07 million. It is projected to garner US$ 114.15 million by 2030 to expand at 9.3% CAGR during 2022–2030.

Based on grade, the South & Central America glioma treatment market is segmented into low grade and high grade. The high grade segment held 78.8% share of South & Central America glioma treatment market in 2022, amassing US$ 92.37 million. It is projected to garner US$ 184.54 million by 2030 to expand at 9.0% CAGR during 2022–2030.

Based on end user, the South & Central America glioma treatment market is segmented into hospital & clinics and ambulatory surgical center. The hospital & clinics segment held 78.8% share of South & Central America glioma treatment market in 2022, amassing US$ 92.35 million. It is projected to garner US$ 180.85 million by 2030 to expand at 8.8% CAGR during 2022–2030.

Based on country, the South & Central America glioma treatment market has been categorized into Brazil, Argentina, and the Rest of South & Central America. Our regional analysis states that Brazil captured 60.5% share of South & Central America glioma treatment market in 2022. It was assessed at US$ 70.93 million in 2022 and is likely to hit US$ 140.93 million by 2030, exhibiting a CAGR of 9.0% during 2022–2030.      

Key players operating in the South & Central America glioma treatment market are Amgen Inc, Biocon Ltd, F. Hoffmann-La Roche Ltd, Merck & Co Inc, Pfizer Inc, Sun Pharmaceutical Industries Ltd, and Teva Pharmaceutical Industries Ltd, among others.